CASE REPORT

Spontaneous spinal subdural haematoma in a patient on apixaban

Ahmad Mchaourab,1 Gwenllian Ying-Huey Evans,2 Richard Austin2

SUMMARY

A 68-year-old man on apixaban presented to the emergency department with back pain following a long-haul flight. Investigations for pulmonary embolus and aortic dissection were negative and he was discharged with analgesia for mechanical back pain. He presented three more times with worsening back pain, third time with urinary retention and the fourth time with lower limb weakness and loss of coordination. He was found to have a spinal subdural haematoma on MRI and transferred to a tertiary centre, where he was managed conservatively and discharged for rehabilitation with good neurological recovery.

BACKGROUND

This is an unusual case presentation of a rare form of iatrogenic back pain that was initially missed in the emergency department (ED). The patient presented multiple times with similar symptoms that progressively worsened and developed neurological deficits. Any patient that presents numerous times within a short time frame should be seen as a red flag, especially if they are anticoagulated.

CASE PRESENTATION

A 68-year-old man normally fully independent with a history of atrial fibrillation, controlled with apixaban, presented to the ED with sudden onset mid-back pain following a long-haul flight. There was no history of trauma. He was investigated for suspected pulmonary embolus (PE) given the history of recent air travel, however D-Dimer was not raised and observations were stable. His pain self-resolved with no focal neurological present. He was discharged with analgesia and a diagnosis of mechanical back pain.

He represented 2 days later with a more severe recurrence of the pain through his shoulder blades, described as a ‘burning’ pain. Due to new nature of the pain, new onset hypoxia seen on arterial blood gas and stiff calves, a CT aortogram was performed to rule out an aortic dissection or PE. As there was no evidence of dissection on the imaging, he was discharged with antibiotics for a presumed infection as some reactive lymph nodes were found.

He presented for the third time the next day as a primary care referral due to urinary retention. 1300mL of urine was seen on bladder scan and he was successfully catheterised. At this time normal power and sensation in his lower limbs were noted and there was normal anal tone on rectal examination. After an assessment by urology it was thought the retention was secondary to constipation, having started codeine recently. Bowels had last opened 3 days previously and an enema was administered in the ED with satisfactory results. He was discharged with laxatives and an indwelling catheter.

The following day after his third discharge he presented for the fourth and final time, with headache, neck stiffness, vomiting and dramatically reduced coordination in his lower limbs. On examination he was alert with no photophobia or confusion, and normal power and sensation in his upper limbs. However, power and coordination were reduced bilaterally in his lower limbs and reflexes were difficult to elicit. A broad-based, ataxic gait was observed. He was admitted and apixaban was stopped due to clinical suspicion of haemorrhagic spinal pathology. Urgent CT of his head showed a small possible subarachnoid haemorrhage and MRI of his spine was initially reported by the radiologist as showing a thoracic syringomyelia in T1–T5 (figure 1), with extension in L4–S1. However, this was later determined to be a spinal subdural haematoma.

After being transferred to a tertiary neurosurgical centre, he was discussed in the spinal multidisciplinary team meeting. The decision made was for conservative management due to the bleeding risk of operating, and that this was a subacute presentation by the time he was transferred; reversal of symptoms were thought to be unlikely with surgical intervention. Had this been an acute presentation it was more likely that reversal of apixaban and surgical intervention would have been carried out. Further imaging was requested to determine if there was a vascular abnormality. Spinal angiogram was abandoned due to intraoperative complications. CT angiogram and magnetic resonance angiogram were performed instead, which showed no vascular abnormality. He remained neurologically stable and was discharged to a spinal injury rehabilitation centre. He made a good neurological recovery and is doing intermittent self-catheterisation with no bowel disturbances. Mobilisation is aided with a tripod stick indoors and a wheelchair outdoors. Repeat MRI 1 month following the initial imaging demonstrated near complete resolution of the haematoma (figure 2).

INVESTIGATIONS

► Bloods.
► CT aortogram.
► CT head.
► MRI.
Reminder of important clinical lesson

- CT angiogram.
- MR angiogram.

DIFFERENTIAL DIAGNOSIS
- PE.
- Aortic dissection.
- Cauda equina.
- Arteriovenous malformation (AVM).

OUTCOME AND FOLLOW-UP
Referred to spinal injury rehabilitation centre. Good, but not complete, neurological recovery with conservative management. Patient performing intermittent self-catheterisation and mobilising with assistance. Repeat MRI showed near complete resolution of the haematoma.

DISCUSSION
Spontaneous spinal subdural haematoma (SSDH) is an extremely rare cause of back pain and often irreversible spinal cord injury. The first known non-traumatic case was described in 1948 in a 16-month-old boy; thought to be secondary to familial haemophilia. While there have been reported cases of SSDH associated with novel oral anticoagulants (NOACs) such as rivaroxaban, there has only been one other reported case associated with apixaban thus far to the best of our knowledge. In a recent literature review of SSDH looking at 122 case reports, 48% of patients had underlying coagulopathies (either through medication or acquired). However, no patients in this series were reported to be on NOACs; the majority of the medication-induced coagulopathy was due to coumarins.

A similar case to ours published in 2017 described a case of spontaneous, non-traumatic SSDH in a patient taking rivaroxaban. The patient developed flaccid paraplegia in her legs a few hours after taking rivaroxaban and the decision was made to perform urgent surgical decompression, after consulting with their haematology department regarding haemostasis concerns. Theoretical guidance was given to control bleeding and the patient underwent spinal decompression with preoperative prothrombin complex concentrate (PCC) and tranexamic acid (TXA) to aid haemostasis. The operation was deemed successful in removing the haematoma and perioperative haemostasis was acceptable, however the patient failed to make a neurological recovery.

Urgent surgical intervention of acute SSDH may be complicated by patient use of anticoagulants, as demonstrated above. Emergency reversal of warfarin and heparins have been well documented, however there were no definitive reversal agents of NOACs until andexanet alfa was trialled in 2015. A comprehensive review published this year explored the reversal of all classes of anticoagulants and highlighted the encouraging results seen by andexanet alfa in trials such as ANNEXA-4. A current ongoing trial, ANNEXA-4 is evaluating the efficacy of andexanet alfa in patients on NOACs with acute major bleeding. A perioperative assessment tool of coagulation status in patients on apixaban was developed by Thrombosis Canada and based assessment on biochemical markers such as anti-factor Xa calibrated to apixaban; a robust marker of anticoagulation while on apixaban. Preliminary analysis of ANNEXA-4 has found that anti-factor Xa activity was reduced by 93% in patients on apixaban. Owing to the promising results, the Food and Drug Administration approved andexanet alfa for reversal of bleeding in patients who are anticoagulated on rivaroxaban and apixaban in May 2018. There are scant studies regarding reversal of NOACs for urgent surgery either through the protocol using PCC and TXA, suggested by the authors of the prior case report, nor by andexanet alfa. Despite this, evidence-based clinical resource hubs such as UpToDate suggest using andexanet alfa as a first line reversal agent for all NOACs.

As reported by the aforementioned literature review, presentation to the ED has been found to be most commonly motor deficits and pain. The most common location for the SSDH is the thoracic spine. There is still no agreed consensus on the best method of management for SSDH, however a comprehensive systematic review found that 86% of cases had a favourable outcome with conservative management, compared with 47%...
of cases where patients underwent surgical management. It is recommended from this review that conservative management may be preferable for patients with mild neurological deficits. As more data becomes available regarding the use ofandexan alfa in the context of surgical intervention, there may be more scope for immediate surgical intervention in the case of future acute SSDH presentations. However, we feel our case also demonstrates that in certain cases, conservative management may also lead to a positive outcome.

### Learning points

- Iatrogenic haemorrhage should be considered in any patient that is anticoagulated and has presented with pain.
- Early diagnosis and referral to neurosurgical unit greatly increases the chances of good neurological recovery.
- Conservative management may be sufficient in certain cases.
- Consider with holding anticoagulation until any form of haemorrhage has been ruled out.
- Early surgical intervention in patients on novel oral anticoagulants may now be possible with the use of andexan alfa, however more data will be needed on the safety of this in the case of emergency reversal.

### Acknowledgements

Since the initial submission, affiliations have changed due to job rotations within a training programme. Dr Ahmad Mchaourab is currently a STS Specialist Registrar in Emergency Medicine at Luton and Dunstable University Hospital. Dr Gwenllian Ying-Huey Rees Evans is a FY2 in Vascular Surgery at Bedford General Hospital.

### Contributors

AM contributed to the conception of the work, obtaining patient’s consent to request confidential data, contacting the tertiary centres for the acquisition of data, analysing and interpreting data and obtaining the patient’s consent to submit the final version of the report for publication. GYHRE contributed to drafting the report, reviewing and extracting the included images. All three authors contributed to critical revision of the report. RA contributed to general advice.

### Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

### Competing interests

None declared.

### Patient consent for publication

Obtained.

### Provenance and peer review

Not commissioned; externally peer reviewed.

### Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

### References

1. Schiller E, Nelligan G, Budtzt-Olsen S. Surgery in haemophilia; a case of spinal subdural haematoma producing paralysis. Lancet Lond Engl 1948;2:842–5.
2. Bang WS, Kim KT, Park MK, et al. Acute spinal subdural hematoma in a patient taking rivaroxaban. J Korean Med Sci 2018;33:e40.
3. Castillo JM, Añanador HF, Manjarrez E, et al. Non-traumatic spontaneous spinal subdural hematoma in a patient with non-valvular atrial fibrillation during treatment with rivaroxaban. Am J Case Rep 2015;16:377–81.
4. Dargazanli C, Lonjon N, Gras-Combe G. Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban); a challenging management. Eur Spine J 2016;25(Suppl 1):100–3.
5. Zaarour M, Hassan S, Thummalapally N, et al. Rivaroxaban-Induced Nontraumatic Spinal Subdural Hematoma: An Uncommon Yet Life-Threatening Complication. Case Rep Hematol 2015;2015:1–5.
6. Collet A, Arboix A, Caiazzo F, et al. Iatrogenic Spinal Subdural Hematoma due to Apixaban: A Case Report and Review of the Literature. Case Rep Hematol 2018;2018:1–5.
7. de Beer MH, Eysink Smeets MM, Koppen H. Spontaneous Spinal Subdural Hematoma. Neurologist 2017;22:34–9.
8. De Vlieger J, Dietvorst R, Semaerel R, et al. Neurosurgery in a patient at peak levels of rivaroxaban: taking into account all factors. Res Pract Thromb Haemost 2017;1:296–300.
9. Curtis R, Schweitzer A, van Vlieten J. Reversal of warfarin anticoagulation for urgent surgical procedures. Can J Anaesth 2015;62:634–49.
10. Ni Ainle F, Preston RJ, Jenkins PV, et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009;114:1658–65.
11. Siegal DM, Curnette JT, Connolly TS, et al. Andexanet Alfa for the reversal of factor Xa inhibitor activity. 2015 http://dx.doi.org/10.1056/NEJMoa1510991.
12. Simon EM, Streitz MJ, Sessions DJ, et al. Anticoagulation reversal. Emerg Med Clin North Am 2018;36:585–601.
13. Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131–41.
14. Thrombosis Canada. Tools. 2013. https://thrombosiscanada.ca/tools/ (cited 3 Dec 2018).
15. Frost C, Song Y, Barrett YC, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014;6:179–87.
16. US Food and Drug Administration (FDA). Accelerated approval: portola pharmaceuticals. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProductsUCM606693.pdf (cited 24 Nov 2018).
17. UpToDate. Perioperative management of patients receiving anticoagulants. https://www.uptodate.com/contents/perioperative-management-of-patients-receiving-anticoagulants#H10171210 (cited 3 Dec 2018).
18. Rettenmaier LA, Holland MT, Abel TJ. Acute, nontraumatic spontaneous spinal subdural hematoma: a case report and systematic review of the literature. Case Rep Neurol Med 2017;2017:1–12.

Copyright 2018 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/ BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow